1 The effects of the protein kinase C inhibitor, Ro 31-8220, on the responses of cultured bovine adrenal chromaffin cells to nicotine, phorbol 12,13-dibutyrate (PDBu) and K+ 4 Ro 31-8220 produced a concentration-dependent inhibition of 5 gM nicotine-stimulated tyrosine hydroxylase activity, adrenaline and noradrenaline secretion and cellular cyclic AMP levels, with an IC50 of about 3 gLM and complete inhibition by 10 LM. At concentrations up to 10 gM, Ro 31-8220 had little or no effect on the corresponding responses to 50 mM K+. 5 A structural analogue of Ro 31-8220, bisindolylmaleimide V, that lacks activity as a protein kinase C inhibitor, had no effect up to 10 gM on PDBu-stimulated tyrosine hydroxylase activity or on nicotinestimulated cyclic AMP levels or noradrenaline secretion and only marginal inhibitory effects on nicotinestimulated tyrosine hydroxylase activity and adrenaline secretion. 6 A structurally related protein kinase C inhibitor, bisindolylmaleimide I, inhibited PDBu-stimulated tyrosine hydroxylase activity with an IC50 of <1 uM and complete inhibition by 3 gM, but had essentially no effect on nicotine stimulated tyrosine hydroxylase activity or catecholamine secretion. 7 The results suggest that Ro 31-8220 is not only a protein kinase C inhibitor but is also a potent inhibitor of nicotinic receptor responses in adrenal chromaffin cells by a mechanism unrelated to protein kinase C inhibition. The results are consistent with Ro 31-8220 being a nicotinic receptor antagonist.
Introduction
Nicotinic stimulation of adrenal chromaffin cells causes acute activation of tyrosine hydroxylase (TOH), the rate-limiting enzyme for catecholamine biosynthesis Zigmond et al., 1989) . This activation is due to increased phosphorylation of three serine residues in the N-terminal regulatory domain of TOH (Haycock & Wakade, 1992; Haycock, 1993) . The increased phosphorylation of all three serine residues and the activation of TOH produced by nicotinic agonists are totally dependent on extracellular Ca2+ Waymire et al., 1988) . At present, it is not clear which kinases mediate the increased phosphorylations on the three serine residues and which of these phosphorylations are responsible for activating TOH.
Stimulation of chromaffin cells and PC12 cells with phorbol esters that activate protein kinase C (PK-C) also activates TOH Tachikawa et al., 1987; Haycock, 1990) . This activation is accompanied by an increase in phosphorylation of two of the same serine residues in TOH that are phosphorylated by nicotinic stimulation (Haycock, 1993) . Furthermore, nicotinic stimulation of chromaffin cells causes a Ca2"-dependent activation of PK-C (TerBush & Holz, 1986) . These findings suggest that PK-C may be one of the kinases involved in mediating the phosphorylation and activation of TOH by nicotinic stimulation.
We have used potent, selective, membrane permeant inhibitors of PK-C to investigate the role of PK-C in the nico-'Author for correspondence.
tinic activation of TOH in intact bovine adrenal chromaffin cells. One of these PK-C inhibitors, Ro 31-8220, is a bisindolylmaleimide compound structurally related to the indolocarbazole staurosporine (Davis et al., 1989; 1992b; Elliott et al., 1990) . Ro 31-8220 acts competitively with respect to ATP to inhibit purified rat brain PK-C in vitro with an IC50 of 10 nM (in the presence of 10 yM ATP: Elliott et al., 1990; Davis et al., 1992b) , and shows little selectivity for different PK-C isozymes . It is more than 100 fold selective for PK-C compared with protein kinase A (PK-A) or Ca2 +/calmodulin dependent kinases such as phosphorylase kinase or Ca2+/calmodulin-dependent protein kinase II (Davis et al., 1989; Elliott et al., 1990) . We have investigated the effects of Ro 31-8220 on nicotinic responses of bovine chromaffin cells and have found it has actions that are not related to its ability to inhibit PK-C. Preliminary accounts of this work have been published (Marley et al., 1994; 1995a) .
Methods
Measurement of TOH activity in bovine chromaffin cells Bovine adrenal chromaffin cells were isolated as described by Livett et al. (1987b) and cultured for two to four days at a density of 55 x 106 cells per 35 ml in 650 ml culture flasks. Cells were harvested, washed and used for determination of TOH activity in situ in the intact cells as described previously (Marley et al., 1995b) . The assay measures the production of of L-[carboxyl-14C]-tyrosine offered to the cells (see Marley et al., 1995b) . TOH activity was measured at 370C over a 10 min period in the presence of agonists. Kinase inhibitors or vehicle were present for a 15 min preincubation period and during the 10 min stimulation period. Stimulation with elevated K+ concentrations was performed by replacing 50 mM of the NaCl in the buffer with 50 mM KCl.
Catecholamine secretion and cellular cyclic AMP responses in bovine chromaffin cells Bovine chromaffin cells were prepared as described by Livett et al. (1987b) and cultured in 24 well or 6 well tissue culture plates for measurement of catecholamine secretion or cellular cyclic AMP responses, respectively. Cells were used two to four days after plating. Cell washes and incubations were performed in the same HEPES-buffered saline (HBS) solution used for the TOH assays (Marley et al., 1995b) . Catecholamine secretion and cellular cyclic AMP responses were measured at 370C over a 10 min period in the presence of agonists. Kinase inhibitors or vehicle were present for a 15 min preincubation period as well as during the 10 min stimulation period. Endogenous catecholamines secreted into the incubation buffer and in cell extracts were measured by h.p.l.c. with electrochemical detection, essentially as described previously (Livett et al., 1987a) . Cellular cyclic AMP levels were determined in cell extracts by radioimmunoassay as described in detail previously 
Results

Effects of Ro 31-8220 on responses to phorbol ester
Ro 31-8220 produced a concentration-dependent inhibition of TOH activation by the PK-C activator phorbol 12,13-dibutyrate (PDBu, Figure la ). Ro 31-8220 had an IC50 of <2 pM and inhibited the PDBu response by 73.5 + 4.7% and by 87 + 3.7% at 3 and 10 pM, respectively (mean from 4 cell preparations). It had no significant effect on basal TOH activity at concentrations up to 3 gM and at 10 gM weakly inhibited basal activity in only 3 out of 15 experiments (compare Figures la, 2a and 2b).
The specificity of the action of Ro 31-8220 in inhibiting the phorbol ester response was assessed in two ways. Firstly, it was tested for its effect on protein kinase A, by using forskolin to activate TOH. Forskolin is known to stimulate cyclic AMP formation by adenylate cyclase, and phosphorylates and activates TOH exclusively through stimulation of PK-A (see George et al., 1989; Haycock, 1993; Marley et al., 1995b) . .
-a ioI-i--recntranann effect on the response to forskolin ( Figure Ib) . Secondly, another bisindolylmaleimide compound, bisindolylmaleimide V (also known as Ro 31-6045), that is structurally related to Ro 31-8220 but lacks activity as a PK-C inhibitor (Elliott et al., 1990; Twomey et al., 1990) Depolarization of chromaffin cells with elevated K+ mimics the effects of nicotinic stimulation in causing a Ca2+-dependent increase in phosphorylation of the same three serine residues in the N-terminal of TOH and a Ca2"-dependent increase in TOH activity Haycock, 1993) . However, at concentrations up to 10 gM, Ro 31-8220 did not inhibit TOH activation by 50 mM K+ (Figure 2b) .
The differential effects of Ro 31-8220 on the actions of nicotine and K + depolarization were unexpected, since these two agents are usually considered to give similar effects on chro- (Figure 3) . Ro 31-8220 also caused a concentration-dependent inhibition of nicotine-induced cellular cyclic AMP levels without affecting the response to K+ depolarization (Figure 4) . Ro 31-8220 had no significant effect on basal catecholamine secretion (not shown) or on basal cellular cyclic AMP levels at concentrations up to 10 pM (Figure 4) .
Effects of bisindolylmaleimides I and V on nicotinic responses
Bisindolylmaleimide V, the structural analogue of Ro 31-8220 that lacks activity as a PK-C inhibitor, had little or no effect on nicotine-induced activation of TOH, catecholamine secretion or cellular cyclic AMP levels ( Figure 5 ). This suggests that the effects of Ro 31-8220 on the nicotinic responses are structurally specific. To determine whether Ro 31-8220 needed to inhibit PK-C to produce its effects on the nicotinic responses, another bisindolylmaleimide inhibitor of PK-C was used, bisindolylmaleimide I (also known as GF 109203X and Go 6850 : Toullec et al., 1991; Martiny-Baron et al., 1993) . This compound produced a concentration-dependent inhibition of TOH activation by PDBu with an IC50 of <1 AIM (Figure 6a ), but had essentially no effect on either TOH activation (Figure 6b ) or catecholamine secretion (Figure 7 ) induced by nicotine.
Discussion
The present results suggest that Ro 31-8220 is not only an inhibitor of PK-C but is also an antagonist of nicotinic cholinoceptors on adrenal chromaffin cells. Its inhibitory action on the nicotinic receptors is not due to inhibition of PK-C since inhibition of PK-C with bisindolylmaleimide I did not mimic the effects of Ro 31-8220 (Figures 6 and 7) .
Ro 31-8220 as a PK-C inhibitor on chromaffin cells
The inhibitory effect of Ro 31-8220 on TOH activation by PDBu is consistent with its known actions as a PK-C inhibitor. Our previous studies have shown that the cyclic AMP-dependent protein kinase (PK-A) appears to be an absolute requirement for activation of TOH by many agents including nicotine, histamine, PACAP-27, PDBu and forskolin (Marley et al., 1994; 1995a,b; . However, the effect of Ro 31-8220 on the PDBu response cannot be ex- plained by it inhibiting PK-A because it failed to inhibit TOH activation by forskolin, an agent known to activate TOH exclusively through PK-A activation (George et al., 1989); Haycock, 1993) . In addition, the lack of effect of Ro 31-8220 on basal TOH activity and TOH activation by forskolin and K+ indicates it does not non-specifically inhibit the tyrosine transporter in the plasma membrane or the TOH enzyme itself, or voltage-sensitive Ca2+ channels. Furthermore, its actions are mimicked by another known PK-C inhibitor, bisindolylmaleimide I, but not by the structurally related compound, bisindolylmaleimide V which lacks activity as a PK-C inhibitor. Taken together, these (Marley et al., 1995a; , which act through other receptor types, is consistent with this conclusion.
There are two possible explanations for the selectivity of Ro 31-8220 in inhibiting the nicotinic responses over those of K+ depolarization. Firstly, Ro 31-8220 may specifically inhibit PK-C and PK-C may need to phosphorylate the nicotinic receptors before they are responsive to nicotinic agonists. Al- ternatively, Ro 31-8220 may be a direct inhibitor of the chromaffin cell nicotinic receptor by an action unrelated to PK-C inhibition. Several of the subunits that comprise nicotinic cholinoceptors are known to be phosphoproteins that are substrates for a variety of kinases including PK-A, Ca2+/calmodulin-dependent protein kinase II, a tyrosine kinase related to PP60c-src and PK-C (Huganir & Greengard, 1987) . PK-C is known to phosphorylate the a and 6 subunits of the neuromuscular junction type of nicotinic receptor, and nicotinic receptor phosphorylation has been shown to increase desensitization of the receptor, hence reducing its responsiveness to nicotinic agonists (see Huganir & Greengard, 1987; 1990) . It is not yet known which types of nicotinic receptor subunits are expressed in chromaffin cells, their stoichiometry in forming functional chromaffin cell nicotinic receptors or whether they are substrates for PK-C. Consequently, it is not clear whether PK-C can regulate nicotinic receptor function in chromaffin cells. In addition, phorbol esters enhance Ca2+ -dependent catecholamine secretion from chromaffin cells (Bittner & Holz, 1990) , suggesting PK-C may have actions other than enhancing nicotinic receptor desensitization in these cells.
If Ro 31-8220 were inhibiting the nicotinic responses of chromaffin cells by inhibiting nicotinic receptor phosphorylation by PK-C, its actions should be mimicked by other PK-C inhibitors. This was not the case: bisindolylmaleimide I almost completely inhibited TOH activation by PDBu at concentrations which had no effect on the nicotinic responses (Figures 6  and 7) . Furthermore, we have also studied the indolocarbazole PK-C inhibitor, CGP 41251 (Meyer et al., 1989) , and this compound also inhibited the response to PDBu at concentrations that did not affect the responses to nicotine (Loneragan & Marley, in press). This strongly suggests that the inhibition of the nicotinic responses of chromaffin cells by Ro 31-8220 is unrelated to its ability to inhibit PK-C.
Taken together, the results indicate that Ro 31-8220 is an antagonist of nicotinic cholinoceptors on chromaffit cells. Although this effect is unrelated to its ability to inhibit PK-C, it is clearly a structurally specific effect since it is not shared by the related compounds bisindolylmaleimides I ore V ( Figures   5-7 clonidine, phentolamine, yohimbine, propranolol, oxymetazoline and neosurugatoxin (Mizobe et al., 1979; Marley et al., 1986; Powis & Baker, 1986; Orts et al., 1987; Bourke et al., 1988; Wan et al., 1988; Cheung et al., 1993 Toullec et al., 1991; Davis et al., 1992a,b; Bit et al., 1993) and many of these are available for further characterization of its structure-activity profile against nicotinic receptors. It will also be of interest to determine the selectivity of Ro 31-8220 for the chromaffin cell form of nicotinic receptor compared with the neuromuscular junction, autonomic ganglia and CNS types of nicotinic receptor.
